The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. Therefore it is not recommended for reimbursement
The NCPE does not consider Vortioxetine (Brintellix®) cost-effective for the treatment of major depressive disorder in adults and therefore is not recommended for reimbursement.
The NCPE does not consider nivolumab (Opdivo®) with ipilimumab (Yervoy®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma and therefore is not recommended for reimbursement at the submitted price.
Following review the NCPE recommends that ivacaftor should not be reimbursed for this indication at the submitted price.
Following review of the company submission, the NCPE do not consider nivolumab to be cost-effective at the submitted price.
Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.
The NCPE considers ramucirumab not to be cost effective as either combination therapy with paclitaxel or as monotherapy, and therefore cannot recommend this drug for reimbursement at the submitted price.
The NCPE considers scaubitril/valsartan (Entresto) a cost-effective treatment for adult patients with symptomatic chronic heart failure with reduced ejection fraction. Therefore reimbursement is recommended.
The NCPE does not recommend the reimbursement of lumacaftor + ivacaftor (Orkambi) for cystic fibrosis patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene at the submitted price. Patients on Managed Access Programme will continue on Orkambi
Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.